Meridian Bioscience Projects FY17 Revenues To Rise 2%; Issues FY18 Guidance

(RTTNews) - Meridian Bioscience, Inc. (VIVO) announced that based on preliminary results, the company expects revenues for fiscal 2017, to be approximately $200.5 million, an increase of 2% compared to the prior year. Earnings per share on a GAAP basis are expected to be $0.50 to $0.51. On a non-GAAP basis, earnings per share are expected to be $0.66 to $0.67.

The preliminary results reflect fourth-quarter revenue of approximately $49.5 million, representing 5% growth compared to the prior year.

For fiscal 2018, net revenues are expected to be between $207 and $212 million, representing growth of 3% to 6%. On a GAAP basis, per share earnings for fiscal 2018 are expected to be between $0.59 and $0.62. On a non-GAAP basis, fiscal 2018 earnings are expected to be between $0.65 and $0.68, resulting in relatively flat earnings compared to fiscal 2017 on a non-GAAP basis.